

20Jan2026

**NOTICE REGARDING OFFER OF REFUNDS TO 340B COVERED ENTITIES**

Baxter Healthcare Corporation (“Baxter”) has recalculated 340B Ceiling Prices for the NDC’s referenced below for the periods of time identified in the table below for each NDC. As a result of the recalculation Baxter has determined that a refund is or may be due to 340B Covered Entities that purchased any of the NDCs identified in the table during the applicable time periods.

Product Name	NDC	Time Period
Cefepime (1g/50mL & 2g/100mL)	00338-1301-41	3Q2008-2Q2022
	00338-1301-48	
Vancomycin (750mg/150mL)	00338-3580-48	1Q2011-2Q2022
Cefazolin (2G INJ, 100mL)	00338-3508-41	4Q2015-2Q2022

Baxter will refund any amount due for the periods 1Q2010 and later directly to the 340B Covered Entity of record without further action from any Covered Entity. Details on the refund and its processing will be provided directly to the 340B Covered Entity by, or on behalf of, Baxter.

Any 340B Covered Entity that believes is owed a refund for NDC 00338-1301 during the period beginning 3Q2008 through 4Q2009 is invited to please contact Baxter at [Medicaid\\_Rebates@Baxter.com](mailto:Medicaid_Rebates@Baxter.com), with a reference to the NDC and time period during which the believed refund applies. Baxter will review such requests received on or by 31Dec2026 and will issue refunds upon validation of the requests.